Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Current Leases (2019 - 2025)

Legend Biotech filings provide 7 years of Current Leases readings, the most recent being $7.4 million for Q4 2025.

  • On a quarterly basis, Current Leases rose 54.17% to $7.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.4 million, a 54.17% increase, with the full-year FY2025 number at $7.4 million, up 54.17% from a year prior.
  • Current Leases hit $7.4 million in Q4 2025 for Legend Biotech, roughly flat from $7.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $7.4 million in Q4 2025 to a low of $1621.0 in Q2 2021.
  • Median Current Leases over the past 5 years was $3.6 million (2022), compared with a mean of $3.7 million.
  • Biggest five-year swings in Current Leases: tumbled 37.77% in 2021 and later soared 218070.95% in 2022.
  • Legend Biotech's Current Leases stood at $911000.0 in 2021, then skyrocketed by 291.11% to $3.6 million in 2022, then fell by 10.89% to $3.2 million in 2023, then skyrocketed by 51.18% to $4.8 million in 2024, then skyrocketed by 54.17% to $7.4 million in 2025.
  • The last three reported values for Current Leases were $7.4 million (Q4 2025), $7.4 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.